A new modality for immunosuppression: targeting the JAK/STAT pathway

This publication has 134 references indexed in Scilit:

• Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation
  Blood, 2004
• Control of Leishmania major in the absence of Tyk2 kinase
  European Journal of Immunology, 2004
• The STATs of cancer — new molecular targets come of age
  Nature Reviews Cancer, 2004
• Cancer immunoediting: from immunosurveillance to tumor escape
  Nature Immunology, 2002
• The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease
  Nature, 2002
• The biology of Stat4 and Stat6
  Oncogene, 2000
• A Specific Inhibitor of Janus Kinase-3 Increases Survival in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis
  Biochemical and Biophysical Research Communications, 2000
• Genetic and Biochemical Evidence for a Critical Role of Janus Kinase (JAK)-3 in Mast Cell-Mediated Type I Hypersensitivity Reactions
  Biochemical and Biophysical Research Communications, 1999
• Human severe combined immunodeficiency: Genetic, phenotypic, and functional diversity in one hundred eight infants
  The Journal of Pediatrics, 1997
• Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor
  Nature, 1996